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Galectin-1 is a lectin recognized by galactoside-containing glycoproteins, and is involved in cancer progression and metastasis.
The role of galectin-1 in radiosensitivity has not previously been investigated. Therefore, this study tests whether galectin-1 is
involved in the radiosensitivity mediated by the H-Ras signaling pathway using cervical carcinoma cell lines. A knockdown of
galectin-1 expression in HeLa cells decreased clonogenic survival following irradiation. The clonogenic survival increased
in both HeLa and C33A cells with galectin-1 overexpression. The overexpression or knockdown of galectin-1 did not alter
radiosensitivity, whereas H-Ras was silenced in both cell lines. Whereas K-Ras was knocked down, galectin-1 restored the
radiosensitivity in HeLa cells and C33A cells. The knockdown of galectin-1 increased the high-dose radiation-induced cell
death of HeLa cells transfected by constitutively active H-Ras. The knockdown of galectin-1 inhibited the radiation-induced
phosphorylationofRaf-1andERKinHeLacells.Overexpressionofgalectin-1enhancedthephosphorylationofRaf-1andERKin
C33A cells following irradiation. Galectin-1 decreased the DNA damage detected using comet assay and c-H2AX in both cells
following irradiation. These ﬁndings suggest that galectin-1 mediates radioresistance through the H-Ras-dependent pathway
involved in DNA damage repair.
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Cancer of the uterine cervix is prevalent in developing
countries. Radiotherapy has a signiﬁcant role in deﬁnitive
and adjuvant therapy. Local recurrence in patients following
radiotherapy presents a challenge because salvaging pre-
viously radioresistant tumors using either radiotherapy or
surgery with concern for normal tissue complications is
difﬁcult. The analysis of our prior study reveals that the overall
incidence of local recurrence is 13% following deﬁnitive
radiotherapy.
1 Clinical trials targeting EGFR
2–4 or COX-2
5–7
failed to improve the treatment outcome; severe side effects
were even noted. Hence, the reconsideration of other mole-
cular targets involving radioresistance will be a future goal.
Galectins are proteins with galactoside-binding glycoproteins.
Clinical evidence of galectin involvement in cancer progression
is increasing.
8 Galectin-1 is associated with a poor prognosis
in head and neck cancer
9–12 and prostate cancer.
13 Because
radiotherapy is among the major therapies of head and
neck, prostate, and cervical cancer, investigating the role
of galectin-1 in radiation response is valuable.
Basedonclinicalevidence,twomajormechanismsofradio-
resistance exist, and galectin-1 may involve both. The ﬁrst
factor is DNA repair. Parliament and Murray
14 reviewed the
clinical evidence of numerous DNA repair genes involving
radioresistance. H-Ras involves DNA repair
15–18 and radio-
resistance.
15,19–21 In addition, galectin-1 can interact with
H-Ras to promote downstream signals.
22,23 The second factor
is tumor hypoxia. Hypoxia is a radioresistance-inﬂuencing
factor for patients with cervical cancer.
24,25 Coincidentally,
hypoxia is associated with galectin-1 expression.
9,10,26
Furthermore, galectin-1 is associated with the progression
of cervical cancer.
27 Overall, this study explored the associa-
tion between galectin-1 and radioresistance in cervical cancer
cells. The results show that galectin-1 mediates resistance to
radiation-induced cell death through H-Ras, but not K-Ras.
Results
Varying expressions of galectin-1 in different cervical
cancer cell lines. To evaluate the role of galectin-1 in the
radiation response of cervical cancer cells, this study ﬁrst
assessed the galectin-1 expression in different cervical cells.
We noted a high expression of galectin-1 in HeLa cells and
an extremely weak expression of galectin-1 in C33A cells
(Figure 1a). Therefore, this study transfected the siRNA of
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www.nature.com/cddisgalectin-1 in HeLa cells for knockdown and transfected the
cDNA in C33A cells/HeLa cells for galectin-1 overexpression.
Transfection of cDNA with green ﬂuorescent protein (GFP)
and galectin-1 increased the expression of galectin-1 in
HeLa and C33A cells (Figure 1a). The siRNA of galecin-1
inhibited galectin-1 expression in RNA and protein levels
(Supplementary Figure S1). In both cells transfected with
GFP and galectin-1, immunoprecipitation (IP) for GFP and
then immunoblotting for galectin-1 revealed positive galectin-
1 (14kDa) in HeLa cells, but not C33A cells (Figure 1b). The
result demonstrated the interaction between endogenous
galectin-1 and fusion protein in HeLa cells. In HeLa cells,
similar cellular distributions of GFP–galectin-1 fusion protein
(green) compared with those of galectin-1 (red) were
observed using confocal microscopy (Figure 1c).
Galectin-1 involves the radioresistance of HeLa and
C33A cells. The next step to examine the role of galectin-1
in the radiation response of cervical cancer cells is to perform
a clonogenic assay using galectin-1 knockdown in HeLa cells
or galectin-1 overexpression in HeLa and C33A cells. HeLa
and C33A cells were transfected with scrambled RNA or
galectin-1 siRNA 48h before 0, 2, 4, 6, or 8Gy of irradiation.
HeLa or C33A cells were transfected with GFP vector or
galectin-1 cDNA and then irradiated. Signiﬁcantly lower
surviving fractions were noted in HeLa cells (Figure 2a)
with galectin-1 knockdown compared with that of scrambled
RNA. The clonogenic survival of HeLa (Figure 2b) cells
was enhanced by galectin-1 overexpression. Galectin-1
knockdown did not alter clonogenic survival in C33A cells
(Figure 2c). However, galectin-1 overexpresssion inhibited
radiation-induced cell death in C33A cells (Figure 2d).
H-Ras, not K-Ras, has a signiﬁcant role in galectin-1-
mediated radioresistance. To assess whether the radio-
resistant effect of galectin-1 was dependent on H-Ras, this
study knocked down H-Ras (Supplementary Figure S2a) to
compare the survival curve in cancer cells with and without
galectin-1 modulation. The galectin-1 knockdown did not
further decrease clonogenic survival of HeLa cells with
H-Ras knockdown (Figure 3a). Galectin-1 overexpression
did not increase clonogenic survival of C33A cells with H-Ras
knockdown (Figure 3b). To investigate the involvement of
K-Ras in galectin-1-mediated radioresistance, this study
performed the same experiment on HeLa cells and C33A
cells with K-Ras knockdown (Supplementary Figure S2b).
Galectin-1 knockdown signiﬁcantly decreased clonogenic
survival of HeLa cells, especially at high doses (Figure 3c).
Galectin-1 overexpression signiﬁcantly increased clonogenic
survival, especially at high doses (Figure 3d). To assess
whether the radioresistance effect of galectin-1 depended
on activated H-Ras, we transfected constitutively active
H-Ras into HeLa cells. Galectin-1 knockdown signiﬁcantly
decreased clonogenic survival of HeLa cells transfected
with constitutively active H-Ras at high doses but not low
doses (Figure 3e), defending against radiation-induced cell
death in HeLa cells with gal-1 knockdown. To investigate
the interaction between Ras and galectin-1, we performed
immunocytochemistry using dual staining with two
antibodies. Positive staining is considered protein–protein
Figure 1 Expression of galectin-1in HeLa and C33A cells. (a) Cells transfected with GFP only,GFP plus galectin-1, or shRNA were compared with cells without a vector.
Lane 1: wild type; lane 2: empty vector; lane 3: shRNA; lane 4: GFP; lane 5: GFPþgalectin-1; lane 6: wild type; lane 7: GFP; and lane 8: GFPþgalectin-1. (b) Interaction
between endogenous galectin-1and GFP-galectin-1fusion protein in C33A and HeLa cells. IP was performed for GFP or galectin-1, and then immunoblotting was performed
for galectin-1 in both cells transfected with fusion protein. A band (43kDa) on each lane indicates fusion protein expression formation. A band (14kDa) on Lane 1 indicates
heterodimer formation of endogenous galectin-1 and fusion protein. (c) Distribution of galectin-1 (red color) and GFP-galectin-1 fusion protein (green color) in HeLa cells
transfected with GFP-galectin-1 fusion protein
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Cell Death and Diseaseinteraction. To study the interaction between H-Ras and
galectin-1 in C33A cells with weak galectin-1 expression, we
noted weak staining in GFP-transfected C33A cells.
However, moderately enhanced dual staining was noted in
galectin-1-transfected cells (Figure 4a). To study the
interaction of K-Ras, we observed extremely weak staining
in GFP-transfected C33A cells. However, mildly enhanced
dual staining was noted in galectin-1-transfected cells
(Figure 4b). Hence, the intensity of H-Ras and galectin-1
interaction was stronger than K-Ras and galectin-1
interaction in galectin-1-transfected C33A cells. In HeLa
cells, the intensity of both H-Ras and galectin-1 was
eliminated in shRNA-transfected cells compared with that
of scrambled RNA cells (Figure 4c). No interaction between
K-Ras and galectin-1 was noted in HeLa cells (Figure 4d).
Anginex (Phoenix Pharmaceuticals, Inc., Burlingame, CA,
USA), used for anti-angiogenesis and as a galectin-1
inhibitor, did not alter the interaction between H-Ras and
galectin-1 (Figure 4e). To conﬁrm interaction between GFP-
galectin-1 and H-Ras, we performed IP on the galectin-1-
overexpressing HeLa and C33A cells (Figure 4f). This study
observed signiﬁcant interaction between galectin-1 and
H-Ras and positive immunoblotting of H-Ras during IP for
GFP in both cells. No interaction between K-Ras and
galectin-1 was noted in HeLa cells, whereas weak
interaction between K-Ras and galectin-1 was noted in
C33A cells. These ﬁndings were consistent with similar
proﬁles of radiosensitivity between wild-type and K-Ras-
knockdown HeLa cells (Figures 2a and 3c) and C33A cells
(Figures 2d and 3d). Therefore, the radioresistant effect of
galectin-1 is H-Ras-dependent.
Galectin-1 enhanced H-Ras activation in cervical cancer
cells following irradiation. Irradiation can activate Ras and
its downstream signals, such as Raf-1 and ERK. To
investigate whether the phosphorylation of Raf-1 and ERK
is inhibited following irradiation by the galectin-1 knockdown,
we used galectin-1 shRNA compared with scrambled RNA.
An increased phosphorylation of both Raf-1 and ERK was
observed in HeLa cells following irradiation. The effects of
phosphorylated Raf-1 and ERK induction were inhibited by
the galectin-1 knockdown (Figure 5). In C33A cells, the
effects of phosphorylated Raf-1 and ERK induction were
enhanced by the galectin-1 overexpression (Figure 5). Thus,
the effects of galectin-1 on Ras activation are through H-Ras.
Figure 2 Galectin-1inhibitsradiation-inducedcelldeath.Clonogenicsurvivalcurveswerecomparedbetween(a)galectin-1knockdownandscrambledRNAinHeLacells
48h after transfection (b) galectin-1 cDNA and GFP vectors in HeLa cells (c) galectin-1 knockdown and scrambled RNA in C33A cells 48h after transfection (d) galectin-1
cDNA and GFP vectors in C33A cells. Cells were irradiated and clonogenic assay performed 12 to 14 days following irradiation. Clonogenic assays were performed during
three independent experiments at each paired condition (with and without galectin-1 modulation). The error bar represents the standard error of mean: *Po0.05, **Po0.01,
and ***Po0.001
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Cell Death and DiseaseGalectin-1 enhanced DNA repair following irradiation.
Because DNA repair is a signiﬁcant factor of radioresis-
tance, this study measured DNA damage in HeLa and
C33A cells at various times following irradiation. Immediately
following irradiation, DNA damage did not differ between
the scrambled RNA and galectin-1 siRNA of HeLa cells.
Similarly, no difference existed between the GFP and
galectin-1 with GFP of C33A cells. However, DNA damage
was severer in the galectin-1-knockdown HeLa cells than in
the control 4 and 24h following irradiation (Figure 6a). DNA
Figure 3 Galectin-1-mediated radioresistance was dependent on H-Ras but not on K-Ras. The knock down of HeLa cells by the siRNA of galectin-1 and H-Ras was
conﬁrmed by reverse transcription-polymerase chain reaction analysis and western-blot analysis in cells transfected with siRNA. Control cells were treated with scrambled
RNA. The clonogenic survival curves were compared among scrambled RNA, H-Ras knockdown/scrambled RNA, and H-Ras knockdown/galectin-1 knockdown. After 48h
following transfection, cells were irradiated, and a clonogenic assay was performed 12 to 14 days after irradiation. Galectin-1 (a) knockdown or (b) overexpression did not
affect the radiosensitivity of cervical cancer cells with H-Ras knockdown. However, galectin-1 (c) knockdown or (d) overexpression altered the radiosensitivity of cervical
cancercellswithK-Rasknockdown.(e)Galectin-1knockdowndecreasedclonogenicsurvivalinHeLacellstransfectedwithmutatedH-Rasathighdosesbutnotatlowdoses.
Clonogenic assays were performed during three independent experiments at each paired condition (with and without galectin-1 modulation). The error bar represents the
standard error of mean: *Po0.05
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Cell Death and Diseasedamage was attenuated in the galectin-1-overexpression
C33A cells than in the control 4 and 24h following irradiation
(Figure 6b). g-H2AX is a marker of DNA damage. The expres-
sion of g-H2AX did not differ between cancer cells with and
without galectin-1 modulation, immediately following irradiation.
However, after 4h of irradiation, enhanced expres-
sions of g-H2AX were observed in the galectin-1-silenced
HeLa cells compared with the scrambled RNA-transfected
Figure4 TheinteractionbetweenH-Rasandgalectin-1ismoreintensethanthatbetweenK-Rasandgalectin-1inC33AandHeLacells.Aninsituproximityligationassay
(PLA)andIPwereperformedfortheinteractionbetweengalectin-1andRas.(a)PLAforgalectin-1andH-RasinC33Acellswithorwithoutgalectin-1overexpression.(b)PLA
for galectin-1and K-Rasin C33A cellswith or withoutgalectin-1overexpression. (c) PLA for galectin-1andH-Rasin HeLa cellswith or withoutgalectin-1knockdown.(d) PLA
for galectin-1 and K-Ras in HeLa cells with or without galectin-1 knockdown. (e) PLA for galectin-1 and H-Ras in HeLa cells with or without the galectin-1 inhibitor anginex
(10mM), which was administered for 24h before cell ﬁxation. (f) IP for galectin-1 and Ras in C33A and HeLa cells transfected with GFP plus galectin-1. IP was performed for
GFP, H-Ras, and galectin-1 before immunoblotting for galectin-1, H-Ras, and K-Ras in both cells
Figure 5 Effects of galectin-1 on the Ras-transmitted downstream signals. Scrambled RNA or galectin-1 shRNA were transfected in HeLa cells. GFP or galectin-1 cDNA
weretransfectedinC33Acells.Thecellswereirradiatedwith6Gyandharvested5or10minlater.ExpressionsofactivatedH-Ras,p-Raf-1,andp-ERKusingwesternblotsin
HeLa and C33A cells were compared with or without galectin-1 modulation
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Cell Death and Diseasecells (Figure 6c). The expression of g-H2AX was attenuated
in the galectin-1-overexpressing C33A cells compared with
the GFP-transfected cells (Figure 6c).
Discussion
This study noted a signiﬁcant difference in radiosensitivity
between the scrambled RNA and galectin-1 siRNA-trans-
fected HeLa cells. However, a small difference in radio-
sensitivity between GFP and galectin-1 plus GFP-transfected
HeLa cells was observed. This is because HeLa is rich in
galectin-1 protein. Hence, the galectin-1 knockdown signiﬁ-
cantly affects the clonogenic assay. By contrast, the over-
expression of galectin-1 may have a ceiling effect on the
clonogenic assay. To solve this problem, we selected
galectin-1-deﬁcient C33A cells (Figure 1a). As expected, the
overexpression of galectin-1 in C33A cells signiﬁcantly
increased clonogenic survival. Thus, this study determined
that galectin-1 is involved in the radioresistance of cervical
cancer cells. To the best of our knowledge, this study is the
ﬁrst investigation of the role of galectin-1 in radioresistance.
We are interested in the mechanism of galectin-1 involved
in radioresistance. H-Ras is among the molecules associated
with radioresistance
20,21 and interacts with galectin-1.
22,23
The common signaling pathways downstream of Ras are
phosphoinositide 3-kinase (PI3K) and Raf-1. Elad-Sfadia
et al.
28 found that galectin-1 involves Ras activation and
diverts Ras signals to Raf-1 at the expense of PI3K.
23
Galectin-1 stabilizes GTP-bound H-Ras and enhances the
activation of Raf-1 and ERK. Our results also demonstrated
that galectin-1 was involved in radiation-induced H-Ras and
Raf-1 and ERK activation. This study noted a weaker
interaction between K-Ras and galectin-1 than between
H-Ras and galectin-1, especially in HeLa cells. In addition,
galectin-1-mediated radioresistance did not exist in H-Ras-
silenced cells and was partially observed in K-Ras-silenced
Figure 6 Galectin-1 enhanced the repair of DNA damage. GFP or galectin-1 plus GFP were transfected into C33A cells. Stable clones of scrambled RNA or galectin-1
shRNA were transfected into HeLa cells. Cells were harvested immediately, 4 or 24h following 6-Gy irradiation. Comet assay was performed. (a) A longer tail was noted in
galectin-1 shRNA compared with scrambled RNA HeLa cells 24h following irradiation. (b) A shorter tail was noted in galectin-1-overexpressed cells compared with GFP-
transfected C33A cells 24h following irradiation. (c) Western blots were performed after harvesting the cells. Greater g-H2AX expression was noted in galectin-1-knocked
down HeLa cells and GFP-transfected C33A cells 4h and 24h following irradiation, respectively
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Cell Death and Diseasecells. The transfection of constitutively active H-Ras could
rescue the radiation-induced cell death of HeLa cells with
galectin-1 knockdown (Figure 3e versus Figure 2a). Addition-
ally, radiation-induced wild-type H-Ras activation was depen-
dent on galectin-1 (Figure 5). The radioresistant effect of
galectin-1 was also wild-type H-Ras dependent. Once H-Ras
is constitutively activated, the downstream signals of radio-
resistance may be independent from galectin-1 following low
irradiation doses (Figure 3e) because the level of GTP-form
H-Ras may be sufﬁcient to alleviate radiation damage.
However, at high doses, endogenous H-Ras and galectin-1
may co-operate H-Ras mutant against radiation. Therefore,
galectin-1 knockdown partially affects radiosensitivity at high
doses, and wild-type H-Ras may have a signiﬁcant role in
galectin-1-mediated radioresistance. Though Paz et al.
22 was
the ﬁrst to discover an interaction between galectin-1 and
H-Ras, we reviewed literature regarding this interaction
and noted that all the studies used transformed cells
instead of cancer cells. In cell lines without transformations,
the expression of GTP-H-Ras is low. However, the expres-
sion of GTP-H-Ras is high in cancer cells (Figure 5). Based
on the study by Paz et al.,
22 galectin-1 interacts with acti-
vated H-Ras. Our study using cancer cell lines reveals that
galectin-1 interacts with H-Ras more than with K-Ras
(Figure 4), and also correlates to the expression of GTP-form
H-Ras (Figure 5). Furthermore, this phenomenon can be
observed through clonogenic assays. The radiosensitive
effect of a galectin-1 knockdown (Figure 2a) is similar to that
of a H-Ras knockdown in HeLa cells (Figure 3a). The survival
ofC33Acells(Figure2c)thataregalectin-1deﬁcientisinferior
compared with HeLa cells (Figure 2a) that are galectin-1 rich.
Both cells possess abundant H-Ras expression. The knock-
down of H-Ras (Figure 3a versus Figure 2a) alters the
radiosensitivity of HeLa cells, whereas the knock down of
K-Ras (Figure 3c versus Figure 2a) does not. However, the
knock down of both H-Ras (Figure 3b versus Figure 2d) and
K-Ras (Figure 3d versus Figure 2d) does not alter the
radiosensitivity of C33A cells. These data prove that H-Ras,
instead of K-Ras, has a signiﬁcant role in radioresistance
in the presence of galectin-1. Increased GTP-H-Ras can
defend against radiation-induced cell death through either
constitutive active H-Ras or galectin-1 and wild-type H-Ras
cooperation.
Concerns exist regarding the function of GFP and galectin-
1 fusion protein. This study noted a heterodimer formation
based on the IP results (Figure 1b). Because almost no
endogenous galectin-1 was expressed in C33A cells
(Figure 1a), we propose that a monomer of fusion protein
possesses the biological function of radioresistance
(Figure 2d). Overexpression of the fusion protein enhanced
radioresistance (Figure 2b) regardless of the abundant
endogenous galectin-1 expression in HeLa cells (Figure 1a).
In addition, both the fusion protein of C33A cells (Figure 4a)
and the endogenous galectin-1 of HeLa cells (Figure 4c)
interacted with H-Ras. Positive immunoblotting of H-Ras
(Figure 4f) was noted in both cells transfected with GFP
plus galectin-1 and immunoprecipitated with GFP. Thus,
fusion protein possesses a similar biological function as
endogenous galectin-1. However, differing amounts of endo-
genous galectin-1 expression was noted between C33A and
HeLa cells. Satelli et al.
29 noted that galectin-1 is silenced by
promoter hypermethylation in human colorectal cancer cells.
None of the cancer cell lines with endogenous galectin-1
expression possessed p53 mutation, whereas 66.7% of the
cancer cell lines without endogenous galectin-1 expression
exhibited p53 mutation. Because p53 mutation is noted in
C33A cells but not in HeLa cells, the association between p53
mutation and galectin-1 promotor hypermethylation is worth
investigating.
Raf-1 and ERK present an interesting issue regarding
radioresistance because the shift of H-Ras transmits down-
stream signals to Raf-1 and ERK through galectin-1. Grana
et al.
30 demonstrated that the mechanism of radioresistance
is related to PI3K and Raf-1, but not to ERK. In addition, a
number of studies support the involvement of Raf-1 in
radioresistance.
31,32 Hence, this study reasonably proposes
that Raf-1 is associated with galectin-1-mediated radio-
resistance. Golding et al.
33 noted that Raf-1 enhanced
radiation-induced DNA damage repair. Ras–Raf–MAPK
signals enhance cell proliferation. However, the high-intensity
Raf signal induces cell cycle arrest through p21.
34 The cell
cycle is associated with radioresistance. A greater amount
of cells in the G1 phase are expected to possess high
radioresistance than cells with a lower G1 fraction.
35 Hence,
we expected the involvement of galectin-1 in cell cycle
regulation and distribution before and after irradiation based
on a number of investigations. Fischer et al.
36 demonstrated
that galectin-1 increased the G1 fraction of the cell cycle
through the induction of p21 transcription. The comet assay
and g-H2AX expression revealed that galectin-1 enhanced
the repair of DNA damage in both HeLa and C33A cells.
Considered together, this study proposes (Figure 7) that
galectin-1 enhances the activation of H-Ras/Raf-1. Raf-1 is
involved in DNA damage repair and cell cycle arrest through
p21. Radiation-induced cell death is inhibited following
galectin-1-mediated H-Ras activation and the subsequent
enhancement of DNA damage repair. Further studies are
Figure 7 A proposed model of cooperation between H-Ras and galectin-1 for
radioresistance. Galectin-1 enhances activation (GTP form) of H-Ras following
irradiation. Galectin-1 potentiates downstream signals of H-Ras, such as Raf-1 and
ERK, that may mediate DNA damage repair
33 and radioresistance.
31,32 Galectin-1
may regulate p21 expression
36 through Raf-1.
34 Hence, Raf-1 may have a
signiﬁcant role in galectin-1-mediated radioresistance
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Cell Death and Diseasesuggested to verify the mechanisms of H-Ras downstream
signaling regarding radioresistance.
This is the ﬁrst study demonstrating galectin-1 to be a
radioresistantmarkerofcervicalcancer.Whethergalectin-1is
also a radioresistant marker of other cancers still requires
conﬁrmation.Tumor-bearingmicewithorwithoutmodulations
of galectin-1 should be investigated in further study of
radiosensitivity. Dings et al.
37 ﬁrst noted that anginex induced
radiosensitization in a murine mammary carcinoma model.
However, during a clonogenic assay, anginex radiosensitized
endothelial cells (ECs) but not cancer cells. In 2006, Thijssen
et al.
38 discovered that anginex could inhibit various effects of
galectin-1, such as angiogenesis, migration, and tumor
progression. They also found that anginex could be detected
at the membrane of intracellular vesicles in ECs. Pilch et al.
39
notedthatanginexdamagedthemembraneofECsbutnotred
blood cells. This study demonstrates that anginex does not
inhibit the interaction of H-Ras and galectin-1 (Figure 4e).
Considered together, anginex may not translocate into cancer
cells. The cell type-speciﬁc cytotoxicity of anginex may
explain its anti-angiogenesis effect. Thus, different rationales
of animal models for radiosensitivity using exist between the
anti-angiogenesis of anginex and gene modulation of galec-
tin-1. The mechanism of radioresistance based on the close
interaction between galectin-1 and H-Ras is worth investigat-
ing. In conclusion, galectin-1 mediates the radioresistance of
cervical cancer cells through H-Ras-dependent pathways.
Targeting galectin-1 may be considered a radiosensitizing
therapy for cancer.
Materials and Methods
Cell culture and antibodies. 293T cells (CRL-11268), HeLa cells (CCL-2),
and C33A (HTB-31) were purchased from the American Type Culture Collection
(ATCC). Cells were grown in DMEM medium (Gibco Life Technologies, Grand
Island, NY, USA) with 10% fetal bovine serum (FBS) (Gibco Life Technologies) and
antibiotics (Gibco Life Technologies) at 371C under an atmosphere of 10% CO2.
The medium was changed every 3 days. Cells were passaged by 0.25% trypsin-
EDTA (Gibco Life Technologies). Subconﬂuent cancer cells were cultured in a 25-T
ﬂask for further experiments. Antibody to galectin-1 (H-45) was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies to phospho-histone
H2AX (Ser139), phospho-Raf-1, Raf-1, phospho-p42/44 ERK, and p42/44 ERK
were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibodies to
a ˆ-actin, H-Ras, and K-Ras were purchased from Abcam Cambridge Science Park
(Cambridge, UK). The secondary antibody (goat anti-rabbit IgG) of the detection
system (alexa Fluor 568) was purchased from Invitrogen (Carlsbad, CA, USA).
Short interfering RNA (siRNA). siRNAs (Invitrogen) were used to silence
galectin-1,H-Ras,orK-Rasaccordingto theprotocolprovidedbythemanufacturer.
siRNA (7.5ml) and Opti-MEM (250ml) were mixed. Lipofectamine 2000 (7.5ml) was
added to the other Opti-MEM (250ml) mixture and mixed for 5min. The diluted
siRNAandLipofectamineweremixedfor 20min.Thereagentswereaddedinto six-
well plates, into which HeLa and C33A cells had been seeded (5 10
5cells/well)
for 4h. Control cells were treated with Stealth RNAi Negative Control Duplex
(Invitrogen).
Stable knockdown of galectin-1. All recombinant lentiviruses were
produced by the transient transfection of 293T cells according to the
manufacturer’s instructions. Brieﬂy, subconﬂuent 293T cells were cotransfected
with 1mg of a hairpin-pLKO.1 vector shLGALS1 (Clone ID TRCN0000057423,
National RNAi Core Facility, Taipei, Taiwan), 900ng of psPAX2, and 100ng of
pMD2.G by Lipofetamine 2000 Transfection Reagent (Invitrogen). After 16h, the
medium was changed, and the recombinant lentivirus vectors were harvested 48h
later and then ﬁltered through 0.45 mm ﬁlters. The virus titers were calculated 72h
following virus infection by counting the number of GFP-expressing foci divided by
the dilution factor. For virus infection, culture cells were incubated with the medium-
diluted culture virus supernatant supplemented with polybrene (8mg/ml) for 6h. To
achieve 495% infection efﬁciency, virus titers of 20 to 40 transduction unit/cells
were used.
Stable transfected cell line. pCMV6-AC-GAL-1-GFP or pCMV6-AC-GFP was
transfectedbyTrueORFdestinationvectors(OriGene,Rockville,MD,USA)with the
Lipofetamine 2000 Transfection Reagent (Invitrogen). The C-terminal sequence
encoding human Gal-1 was cloned into pCMV6-AC-GFP. To transfect HeLa or
C33A cells with the plasmid vector, cells were plated into 24-well plates (2 10
5
cells per well) and allowed to adhere for 4 to 6h. Lipofectamine 2000 (Invitrogen)
was used for the transfection. After pCMV6-AC-GAL-1-GFP or pCMV6-AC-GFP
transfection, the cells were cultured for 24h. Then the medium was replaced with
fresh medium supplemented with 10% FBS. G418 was used for selection; at the
lowest drug concentration, G418 resulted in massive cell death after 3 days and
killed all the cells within 2 weeks. Cells were diluted at a ratio of 1:10 into fresh
growth medium 24h after transduction; then, a selective medium with 600 to
1000mg/ml of G418 was added to stable cell lines the next day. The transducted
cells were trypsinized, collected, and resuspended for ﬂow cytometry to determine
the percentage of green ﬂuorescent cells at 48h following transfection.
Measurement of GFP expression using ﬂow cytometry. We placed
approximately 10
5 cells into a 12 15mm test tube and washed them once with
PBS by centrifugation for 5min at 300 g and 2 to 81C. Supernatant was removed
through aspiration or rapid decanting, and 500ml of cold PBS was added to the cell
pellet. Then, 500ml of cold, buffered 2% formaldehyde solution was added. The
mixture was incubated at 2 to 81C for 1h. The cells were spun down by
centrifugationfor 5min at 300 g and2 to81C.Supernatantwas removedby rapid
decantingandthecellswerewashedoncewithcoldPBS;then,1mlof70%ethanol
was added at  201C to the cell pellet with the tube sitting on a vortex. The cell
suspension was incubated overnight at 2 to 81C; then, cells were spun down by
centrifugation for 5min at 300 g and 2 to 81C. Supernatant was removed by
aspiration or rapid decanting, and 1ml of a solution containing 40 mg/ml of
propidium iodide (PI) and 100mg/ml of ribonuclease A was added. The cell
suspension was incubated at 371C in dark conditions for 30min. The samples were
ﬁltered through a nylon mesh to remove clumps before acquisition on a ﬂow
cytometer.
Stable transfection of constitutively active H-Ras in HeLa
cells. Retroviral packaging 293T cells (1 10
6) were seeded in a 10-cm dish,
incubated for 24h, and then transfected by Fugene 6 (Roche, Roche Applied
Science, Indianapolis, IN, USA) with 1mg retroviral plasmids. The retroviral
plasmids pBabe puro H-Ras G12V T35S and pBABE-puro control were obtained
from Addgene (Cambridge, MA, USA). After 60h, the retrovirus-containing medium
was ﬁltered (0.45-mm ﬁlter; Acrodisc Syringe, Pall Corporation, Port Washington,
NY, USA), concentrated 50-fold (from 25ml to 500ml), and titrated. The HeLa cells
were plated at 70 to 80% conﬂuence in a 10-cm dish at night before infection. Each
infectionused100mloftheconcentratedvirus(MOI0.5)supplementedwith8mg/ml
of polybrene (Sigma-Aldrich, St. Louis, MO, USA). The infected HeLa cells were
selected in media containing 2mg/ml of puromycin for stable cell lines.
Reverse transcription-polymerase chain reaction (RT-PCR).
Total RNA was extracted from the cells using the Trizol reagent (Invitrogen)
accordingto themanufacturer’sinstructions.ThetotalRNA (1mg)was then reverse
transcribed using SuperScript III Reverse Transcriptase (Invitrogen). The RNA
contentwas measuredusing260/280UVspectrophotometry. Thefollowing primers
were used: Gal-1: forward 50-GCATGCATGGCTTGTGGTCTGGTCGC-30 and reverse
50-AAGCTTTCAGTCAAAGGCCACACATTTGA-30. H-Ras:forward 50-ATGACGGA
ATATAAGCTGGTGG-30 and reverse 50-TCAGGAGAGCACACACTTGCAGC-30.
K-Ras: forward 50-ACTGAATATAAACCTTGTGGTAG-30 and reverse 50-TCAAAG
AATGGTCCTGGACC-30. The internal control was b-actin.
Irradiationandclonogenicassay. Cellsofdifferentconditions(scrambled
RNA, siRNA, overexpression, or GFP) were irradiated in 25T ﬂasks. For the
clonogenic assay, 0, 2, 4, 6, and 8 Gy were delivered using a linear accelerator.
Cells (100–10000/well, according to the radiation dose) were plated in six-well
plates immediately following irradiation. In the 1 to 2 weeks following irradiation,
glutaraldehyde (6.0% v/v) and crystal violet (0.5% w/v) were added to ﬁx and stain
colonies, respectively. Cells were counted using a stereomicroscope. A colony was
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0Gy in each condition was according to the plating efﬁciency (PE) (Table 1). The
surviving fraction equaled the number of colonies/(number of cells plated PE).
The survival curve was drawn according to the survival rate (log) and dose.
IP and western blotting. Cells (1 10
7) were lysed in RIPA buffer (150mM
NaCl, 50mM Tris-HCl (pH 7.4), 1% NP40, 1mM PMSF, 1 Roche complete mini
protease-inhibitor cocktail, and 1 Pierce phosphatase-inhibitor cocktail). Co-IP
was performed using the Catch and Release v2.0 Reversible Immunoprecipitation
System (Millipore) according to the manufacturer’s instructions. The immuno-
precipitates or protein extracts (50mg) of cells were heated at 941C for 3min,
resolved by 10% SDS-PAGE, and electrotransferred to PVDF membranes using
semi-dry transfer. The membranes were blocked for 1h at room temperature with
PBS containing 5% milk powder, then incubated with the primary antibody (diluted
concentrations of galectin-1 1:1000, Raf-1 1:500, pRaf-1 1:1000, ERK 1:2000,
pERK 1:2000, and actin 1:10000), and subsequently incubated with the
horseradish peroxidase-conjugated secondary antibody (diluted concentration
1:3000; room temperature for 45min). Following application of the peroxidase-
conjugated secondary antibodies (Santa Cruz), the blots were developed using a
chemiluminescent HRP substrate (Immobilon Western, Millipore, Billerica, MA,
USA) for 1min and then transferred onto a ﬁlm (Amersham Hyperﬁlm MP, GE
healthcare, Little Chalfont, UK).
H-Ras activation assays. HeLa or C33A cells were lysed in a RIPA buffer
containing 10mM of Tris-HCl (pH 7.6), 150mM of NaCl, 10mM of MgCl2,1 %o f
NonidetP-40,1mMof phenylmethylsulfonylﬂuoride(PMSF),10mg/mlof leupeptin,
and 10U/ml of aprotinin. Lysates were centrifuged at 14000g for 30min at 41C.
The resulting supernatants were incubated for 1h at 41C with 20mg of Raf-1 RBD
Agrose immobilized onto glutathione Sepharose beads (Cell Biolabs, San Diego,
CA, USA). After incubation, the beads were collected by centrifugation for 10s at
14000g and washed with 1 Assay buffer three times. The bound proteins were
then analyzed by immunoblotting using the anti-H-Ras antibody.
Comet assay. The comet assay was performed using the CometAssay kit
(Trevigen Inc., Gaithersburg, MD, USA), following the manufacturer’s instructions.
Brieﬂy, an aliquot of 50ml of cells (1 10
5cells/ml) was added to 500ml of molten
LM agarose (0.5% low-melting agarose)stored at 371C. Upon mixing the sample, a
75-ml aliquot was pipetted onto an area of the comet slide. The slide was incubated
at41Cfor10mintoacceleratethegellingoftheagarosediscandthentransferredto
a pre-chilled lysis solution for 10min at 41C. A denaturation step was performed in
an alkaline solution (0.3M NaOH, 1mM EDTA) at room temperature (RT) and
shieldedfrom light for 5min. Theslide was then transferredto 1 TBE (10mM Tris
(pH7.5),1mMEDTA) for5minto neutralizebeforeundergoingelectrophoresisina
horizontalchamberinfresh1 TBEat1V/cmfor10min.Theslidewasﬁxedinice-
cold, 70% methanol for 5min and air dried. For observation, the samples were
stained with SYBR Green (Molecular Probes, Eugene, OR, USA), diluted to
1:10000 in 10mM of Tris-HCl, pH 7.5, 1mM EDTA, and observed using a
ﬂuorescence microscope with a 490-nm ﬁlter.
In situ proximity ligation assay (PLA). To investigate the protein–protein
interaction, this study used the Duolink reagent kit (Olink Biosciences, Uppsala,
Sweden). We seeded 1 10
3 cells in 200ml of medium into the chamber slide for
culture. Cells were ﬁxed in 1% paraformaldehyde for 15min and washed by Wash
Buffer A for 5min twice. Cells were incubated with a blocking solution at 371C for
30min, and then washed with Wash Buffer A for 5min twice. The procedures for
administrating the primary antibodies (galectin-1 versus H-Ras or galectin-1 versus
K-Ras), PLA probes, hybridization, ligation, ampliﬁcation, detection, and mounting
followed the manufacturer’s recommended protocol. The cells were observed using
a ﬂuorescence microscope (Axio Observer Z1, Carl Zeiss MicroImaging, Inc.,
Welwyn Garden City, UK), and photographed using an integrated camera with the
appropriate ﬁlter for detection.
Confocal microscopy for the distribution of GFP-galectin-1
fusion protein. To compare the distribution of transfected GFP-galectin-1
fusion protein, we used a confocal microscope to observe galectin-1 staining and
GFP expression. HeLa cells with GFP-galectin-1 fusion protein transfection were
ﬁxed in 1% paraformaldehyde for 15min and washed using PBS for 5min twice.
The cells were incubated with a galectin-1 antibody at 371C for 30min, and then
washed using PBS for 5min twice. The cells were also incubated with a secondary
antibodyat371Cfor30min,andthenwashedusingPBSfor5mintwice.Finally,the
cells were incubated with a DAPI for 10min and washed using PBS for 5min twice.
After mounting, the cells were observed using a confocal microscope (VivaTome,
Carl Zeiss MicroImaging, Inc.,). The procedure was performed according to the
manufacturer’s instructions. Red and green ﬁlters were used to observe galectin-1
and GFP, respectively.
Statistics. A comparison of the clonogenic assay of each pair was performed
using a paired t-test. A P-value o0.05 was considered statistically signiﬁcant.
Statistical analyses were performed using Statistical Package for Social Sciences
version 17.0 (SPSS, Chicago, IL, USA).
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